Gold prices steady ahead of Fed decision; weekly weakness noted
NEW YORK - Management consulting firm Oliver Wyman, a division of Marsh McLennan (NYSE:MMC) - a $107 billion market cap company with "GOOD" financial health according to InvestingPro analysis - announced an agreement to acquire healthcare analytics business Validate Health, in a transaction expected to close this summer, according to a press release statement. Financial terms were not disclosed.
Validate Health specializes in analytics that help healthcare providers and Accountable Care Organizations manage costs, risk, and performance. The company will join Oliver Wyman Actuarial, a specialized business within Oliver Wyman that provides actuarial services to various clients including insurers and healthcare providers. This acquisition aligns with Marsh McLennan’s strong market position, which has generated $25 billion in revenue over the last twelve months with a healthy 44% gross profit margin.
The acquisition aims to strengthen Oliver Wyman’s capabilities through analytics and technology solutions that help clients optimize programs, manage risk, and enhance patient outcomes.
"This acquisition allows us to not only meet that moment but lead it," said David Weinsier, Partner and Global Life and Health Leader for Oliver Wyman Actuarial.
Andrew Webster, Validate Health Co-Founder, described the deal as "a milestone moment," adding that joining Oliver Wyman would provide "the reach, actuarial and insurance expertise, and complementary skillsets to supercharge" their mission.
Validate Health provides actuarial and financial optimization services for Accountable Care Organizations, reconstructing Centers for Medicare and Medicaid Services methodology using computer models for various healthcare programs.
Oliver Wyman is a business of Marsh McLennan (NYSE:MMC), a global risk, strategy and people advisory firm that has maintained dividend payments for 55 consecutive years and currently offers a 1.5% dividend yield. According to InvestingPro, which provides detailed analysis of 1,400+ US stocks, MMC currently appears overvalued relative to its Fair Value. Discover 8 more exclusive InvestingPro Tips and comprehensive financial metrics by subscribing today.
In other recent news, Marsh McLennan reported its financial results for the first quarter of 2025. The company achieved an adjusted earnings per share (EPS) of $3.06, slightly exceeding the forecasted $3.03. However, revenue came in at $7.06 billion, falling short of the anticipated $7.09 billion. Despite this revenue miss, the company experienced a 9% increase in consolidated revenue year-over-year, with underlying revenue growth of 4%. Marsh McLennan also reported an 8% rise in adjusted operating income, reaching $2.2 billion. The company continues to focus on innovation, highlighted by the launch of an AI-powered platform. Additionally, Marsh McLennan repurchased $300 million in stock during the quarter. Looking forward, the company expects mid-single-digit underlying revenue growth for the remainder of the year, while remaining cautious about the potential impacts of ongoing trade negotiations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.